Prospectus for Genyi Sheng Pharmaceutical industry with three big doubts two married motherboard

At the end of 2009, after the impact of the panel was not, Chinese patent medicine production Enterprise Jilin Province Ji ' an Yi Sheng Pharmaceutical Co., Ltd. (hereinafter referred to as "Yi Sheng Pharmaceutical") finally passed the SFC on February 21 Audit committee.　　As the first year in the year of the rabbit was only issued new shares, Yi Sheng Pharmaceutical industry in the suspected loss of state capital, packaging products originality and the cover-up of the safety of the drugs produced in the year of the Rabbit's IPO market cast a shadow. The revised prospectus for the first listing of Yi Sheng Pharmaceutical industry is not, the investment project of the construction period of non-woodland ginseng project is one of the main reasons, but the historical contribution of the enterprise, the nature of the changes involved in the issue can not be ignored.　　In the new prospectus for 2011 years, not only will the investment project "makeover", the removal of the operation cycle of 13 years of non-woodland ginseng project, more importantly, with major flaws, suspected state capital loss of the historical contribution and share transfer part of the big cut. According to the 2009-year prospectus, Ji ' an Pharmaceutical Co., Ltd. (Yi Sheng Pharmaceuticals predecessor) was founded in June 11, 1997, as a wholly state-owned enterprises.　　Founded in November 1970, the local-owned enterprises, Ji ' an pharmaceutical factory value of more than 30 million yuan assets by Ji ' an Pharmaceutical Co., Ltd. in the bag. Since June 25, 1998, Jian State-owned Assets Management Bureau and Zhang Yixie, Shiliaomin, Curvelet, Li Fangrong, Ying, Li Tiejun signed the "Ji ' an Pharmaceutical Co., Ltd. of the sale of property rights," Ji ' an Pharmaceutical Co., Ltd. all net assets sold to the above 6 people, the price is 1.294 million yuan.　　This is the net asset value assessed by Ji ' an Pharmaceutical Co., Ltd. as at May 31, 1998. At this point, Zhang Yixie and other 6 people at ultra-low prices for housing, machinery and equipment, land and liquid assets. And the 2011 version of the prospectus deleted the Ji ' an Pharmaceutical Co., Ltd. to Ji ' an pharmaceutical factory asset acquisition and other related circumstances.　　Public information shows that Zhang Yixie has been appointed director of the Pharmaceutical factory in Ji ' An, Shiliaomin, director of the Pharmaceutical factory of Ji ' an, deputy director of the Institute, Curvelet, Li Fangrong, Ying have been appointed as the deputy director of Ji ' an pharmaceutical factory, Li Tiejun was the chief of finance of Ji ' an pharmaceutical factory. "The end of the 90 is the peak of the country retreat DPP, neither the asset evaluation nor the transfer of state-owned shares of the detailed laws and regulations, there are many state-owned enterprises in charge of the company to use their familiarity and some accounting methods before the acquisition of the asset prices depressed enterprises, many state-owned enterprises were　　An investment banker, who declined to be named, told the newspaper.　　Concealing and packing in addition, the Yi Sheng Pharmaceutical industry also has a concealed product safety problems and excessive packaging products suspected. Food and Drug Administration of Anhui Province in the second half of 2008 drug quality Bulletin unqualified list (eight), Jilin Province Ji ' an Yi Sheng medicineIndustry Co., Ltd. production of 10ML:0.4G injection (lot: 0704121; specification:) There are visible foreign bodies; in the second quarter of 2007, Hubei Province Food and Drug Administration, drug quality Bulletin unqualified list showed that Sheng Mai pharmaceutical production of Shengmai injection (lot number: 0612221 Specification: 10ml) There are visible foreign bodies. In addition, Yi Sheng Medicine, soothe the nerves of the brain tablets, children, such as Qingre Ling products in Zhejiang, Guizhou, Shenzhen and other provinces and cities of the FDA unqualified products list, the earliest can be traced back to 2003 years.　　In the prospectus of the Yick Shing Pharmaceutical industry, a list of the award-winning records of its various medicines is given, but none of the items mentioned above are mentioned. "The product quality of Chinese herbal injections is very difficult to control and will produce a lot of clinical problems," said a sales manager of a listed pharmaceutical company in an interview with the newspaper. After 2008, Chinese herbal Medicine injection has been a continuous medical accident, many hospitals have refused to enter Chinese medicine injections. The prospectus also mentions the risk of imitation after the expiration of Shengmai injection, but emphasizes the difficulty of imitation of the product. But the industry, this product is actually very popular, "are from the ancient" ginseng and wheat scattered, raw materials are ginseng, and Schisandra chinensis, the name of different enterprises.　　said the sales manager. The above phenomenon and the information disclosed by the Securities and Futures Commission should be true, accurate and complete, and there should be no false records, misleading statements or major omissions.　　Reporter noted that the Yi Sheng pharmaceutical sponsors also from 2009 Wealth Securities into 2011 years of livelihood Securities. As of press, Yi Sheng Pharmaceutical related leaders to travel on the basis of the refusal of reporters on the related issues of the interview.